frontMIND Trial Results

Dr. Graff presents the frontMIND trial, which evaluated tafasitamab plus lenalidomide added to R-CHOP (Tafa-Len-R-CHOP) versus R-CHOP in patients with high-intermediate and high-risk DLBCL (IPI 3-5). The trial demonstrated a meaningful progression-free survival benefit: over 8% difference at 2 years and approximately 6.6% at 3 years favoring the tafasitamab-based regimen.

A notable design feature was allowing patients to start therapy based on local pathology assessment before awaiting central laboratory confirmation. When the analysis was restricted to centrally confirmed DLBCL, the progression-free survival benefit strengthened to approximately 10%, supporting that higher-risk patients with truly confirmed disease biology derive the greatest benefit.

Dr. Graff highlights that unlike POLARIX, frontMIND showed benefit regardless of cell of origin (both germinal center B-cell and activated B-cell subtypes benefited), IPI score, and age. This potentially simplifies selection for community oncologists who may have incomplete cell-of-origin data.

The short diagnosis-to-treatment interval requirement (within 28 days) means the R-CHOP control arm likely enrolled a higher-risk real-world population, suggesting the comparator arm's outcomes may reflect more aggressive disease than typical frontline trials.

Dr. Johnson discusses toxicities with Tafa-Len-R-CHOP, noting close to 70% neutropenia rates, numerically higher treatment discontinuation versus R-CHOP, and the need for pegylated granulocyte colony-stimulating factor support, anti-infective prophylaxis, and aspirin prophylaxis for venous thromboembolism risk from lenalidomide. He discusses lenalidomide dosing flexibility and renal function monitoring.